Navigation Links
Minimizing side effects from chemoradiation could help brain cancer patients live longer
Date:4/19/2011

PHILADELPHIAMinimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

The researchers found that the occurrence of early side effects, such as fatigue and loss of short-term memory, that manifest during or soon after treatment is significantly associated with both late side effects (after 90 days) and overall survival in patients who suffer from malignant brain tumors, such as glioblastoma.

High-grade glioma patients who did not experience neurological side effects during chemoradiation for the brain cancer were found to have lived 4 months longer compared to those who did experience such effects.

The findings suggest the importance of normal tissue damage in determining long-term survival and how minimizing side effects could end in more positive outcomes.

The team reports their findings from a retrospective analysis of high-grade glioma patients from the Radiation Therapy Oncology Group (RTOG) database.

"As survival in glioblastoma multiforme increases, the prevention of treatment related side-effects becomes more important," said Yaacov Richard Lawrence, MRCP, an Assistant Professor in the Department of Radiation Oncology at Thomas Jefferson University and director of the Center for Translational Research in Radiation Oncology at Sheba Medical Center in Israel.

"It is generally considered that the only way to improve survival in malignant brain tumors is to more effectively attack the tumor," Dr. Lawrence said. "Fascinatingly, our research suggests that damage to surrounding normal tissue may also play a role in determining a patient's long term outcome."

There are approximately 17,000 primary brain tumors diagnosed in the United States each year, 60 percent of which are gliomas. The most common and malignant glioma is glioblastoma, the type of brain cancer Senator Ted Kennedy was diagnosed with and died from.

Standard treatment for the cancer typically includes surgery, radiation and chemotherapy after the tumor is identified. It is often impossible to determine whether these treatments, the combination of these treatments or the tumor itself cause neurological symptoms, which include fatigue, headache, nausea, motor/sensory disturbance, short-term memory loss and/or seizures.

For the study, researchers analyzed data amongst 2,761 patients from 14 RTOG radiation therapy glioma studies that accrued patients from 1983 to 2003. Patients considered were more likely to have side effects if they were older, frailer, had more symptoms, and were receiving radiation twice daily.

"Our results support the personalized approach to brain tumor management currently being developed within the Jefferson Multidisciplinary Brain Clinic, and emphasize the importance of minimizing side effects," Dr. Lawrence said.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Mental Health Effects Linger After Tsunami, Study Finds
2. Estrogen treatment with no side-effects in sight
3. Effects of a large reduction in alcohol prices on mortality in Finland
4. CO2 capture: Health effects of amines and their derivatives
5. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
6. Social Media Has Good and Bad Effects on Kids: Experts
7. Predicting serious drug side effects before they occur
8. Protein could be used to treat alcohol effects on pancreas
9. Sexual Side Effects From Propecia, Avodart May Be Irreversible
10. Effects of alcohol on risk factors for cardiovascular disease
11. Seniors Concerned About Side Effects of Heart Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: